secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193125-24-002861
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports ~$200M cash; DSMB clears third patient in Rett syndrome trial
-------------------------------------------------------------------------------

- DSMB cleared third pediatric patient for dosing in NGN-401 Phase 1/2 for Rett syndrome; dosing expected early Q1 2024.
- UK MHRA approved CTA for NGN-401, enabling trial expansion beyond US.
- Ended 2023 with ~$200M cash; cash runway into 2H 2026.
- Plan to report interim Phase 1/2 data for NGN-401 in 4Q 2024 and NGN-101 in 2H 2024; FDA discussions for NGN-101 in 2H 2024.
- Extended research collaboration with University of Edinburgh by three years; plan to advance one discovery product into clinic in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000119312524002861/0001193125-24-002861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000119312524002861/d828702d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-002861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer